This study highlights the profound impact PTI can have on a highly palliative patient cohort previously deemed beyond therapeutic hope. With 41 % of these patients still alive after a median follow-up of 50 months, PTI offers a potential lifeline for those facing advanced, treatment-resistant cancers. This approach generated also distant immunogenic anti-tumor responses, offering a promising new avenue for the treatment of advanced cancers.
Keyphrases
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- clinical trial
- peritoneal dialysis
- study protocol
- lymph node
- prognostic factors
- case report
- randomized controlled trial
- intellectual disability
- phase iii
- autism spectrum disorder
- climate change
- young adults
- replacement therapy
- childhood cancer